Defense | Marit Sandberg | 21.03.2025

FACULTY OF MEDICINE

UNIVERSITY OF BERGEN

DISPUTAS – PH.D.-GRADEN

Marit Sandberg

Candidate from Clinical Institute 2

Main Supervisor: PhD Elisabeth Leirgul
Co-supervisors: Professor Nina Øyen and PhD Ferenc Macsali

Trial Lecture: Friday, March 21, 2025, at 10:15 AM

Location: Auditorium, Glasblokkene 8, Haukelandsbakken 1

Assigned Topic: “Maternal cardiovascular disorders during pregnancy: Impact on fetal-neonatal and long-term child health”

Disputation: Friday, March 21, 2025, at 12:15 PM

Location: Auditorium, Glasblokkene 8, Haukelandsbakken 1

Thesis Title: “Childbearing in women with congenital heart disease. A nationwide cohort study from Norway 1994-2014”

  1. Opponent: Professor II Meryam Sugulle
  2. Opponent: Professor Lars Henning Pedersen
  3. Committee Member: Associate Professor Elham Baghestan

The disputation will be led by Professor Jone Trovik.

OSKE 2025

Hi everyone!

Spring’s most beautiful adventure is approaching rapidly, and we therefore remind you to sign up to help! 😄

OSKE12 takes place on June 5th, and OSKE6 is on June 12th.

Link to sign-up form

We need all good hands on deck to make this happen!

This is a fantastic opportunity to meet colleagues across institutes and faculties. We also hope that you have the opportunity to join!

If there are any questions or anything else, just contact me.

This is going to be great! 😎

Joint working environment survey (FAMU) at UiB 2024-2025

On March 24th, all employees with a 40% position or more will receive a questionnaire by email. There have been significant changes in the survey since last time, some of the changes are:

  • Now only asking about “management” as a function – not “my manager”
  • More about role conflict and mastery climate
  • New questions about:
    • Psychological safety
    • Unacceptable behavior

The survey gives you, as an employee, an opportunity to say something about how you are doing at work and how to influence your own work environment.

All employees at UiB are expected to contribute to a good working environment in their units, this time by responding to the work environment survey and participating in the follow-up of it.

 

Video for international employees:  Joint work environment survey at UiB 2024-2025

Kay Gastinger from Inventas at Eitri on Friday, March 14

The development of medtech products is characterized by a long time to market and requires significant equity financing to succeed. When launching a product in the medtech sector, there is an enormous jungle of words to navigate. Especially, the regulatory requirements are many and constitute a vast and unknown territory for entrepreneurs and investors. At Inventas, we have nearly 30 years of experience in product development and have developed a methodology (or playbook, if you will) for how we can adapt product, business, and regulatory roadmaps with a tailored go-to-market strategy. In the presentation, we will emphasize the success factors and pitfalls you will encounter in the roadmap and how we can adjust them both in terms of development stages and timing. This will enable you to develop a product (or a startup on a development path) in the fastest and most cost-effective way, without taking illegal shortcuts.

https://www.inventas.no/

https://www.linkedin.com/events/vaffelpitchp-eitrimedkaygasting7304149937754107905

 

Bergen Company Revolutionizes Diabetes Treatment

Monday, March 17, 2025, 11:30 AM – 3:00 PM

A record number of people are being diagnosed with diabetes. The Bergen-based company Lifecare is now contributing to revolutionizing patient safety and comfort through groundbreaking methods for monitoring glucose levels.

To shed light on developments in continuous glucose monitoring (CGM), Eitri, the Bergen Chamber of Commerce, and Lifecare have gathered renowned international experts for this exciting symposium.

Link to the event

Leader of the week

The report “Health Industry Export”, prepared by Menon Economics with input from several stakeholders, including LO, NHO, Abelia, IKT-Norge, the Norwegian Association of Pharmaceutical Manufacturers (LMI), the Directorate of Health, the Research Council of Norway, and the Oslo Cancer Cluster, was published recently.

While there are signs of increased revenue, employment, and exports within this sector, there is a negative trend in R&D investments, industrial production, and general investments. The profitability of the health industry has weakened in recent years. The pharmaceutical industry accounts for 74 percent of the health industry’s total exports, but a few large pharmaceutical companies represent a major share.

The pharmaceutical industry is an example of an R&D-intensive sector, and the report reveals challenges such as declining use of NRC SkatteFUNN and fewer patents. The number of SkatteFUNN projects, which are intended to stimulate increased R&D in the business sector, has fallen by 17% from 2021 to 2023.

Meanwhile, researchers in Norwegian academic institutions are beginning to feel the economic tightening affecting the sector. The 2024 report from the Research Association’s survey detailing employees’ experience clearly shows researchers’ concerns that the lack of investment in the field will result in weakened research quality and reduced innovation potential. They fear less time and energy for actual research activities, applying for external funding, and not least for the creative process of coming up with new ideas. Innovation is a surplus phenomenon that requires energy, time, and forums that facilitate interdisciplinary meetings. Outcomes may take time to materialize, and will not be visible in the next annual report.

Against this background, the findings in the Menon report may not be so surprising. The gap between ambitions and conditions becomes apparent. Perhaps the new situation will drive innovation according to the saying “necessity is the mother of invention”. Innovative approaches can be part of the solutions to present challenges in and of themselves. It remains to be seen how the sector will adapt to the new realities, but it is clear that both challenges and opportunities are ahead.

Launch of the national report for subject evaluation of medicine and health subjects (EVALMEDHELSE)

Digital: The event is streamed
April 8 at 13.00–14.30

Subject evaluation of medicine and health subjects has taken place since 2023. And the national report will be published on 8 April 2025.
The aim of the evaluation is to assess the quality of research within medicine and health sciences in Norway. We also look at the framework conditions for the research and how relevant it is for important areas of society.

The evaluation comes with recommendations to the institutions, the Research Council and the ministries.This is the second evaluation within life sciences. Subject evaluation of bioscience (EVALBIOVIT) was launched in March 2024.
A total of 68 administrative units and 317 research groups have been evaluated by three sector-specific evaluation committees and 18 international expert panels. The leaders of the eight evaluation committees have prepared a national report on medicine and health-related research, which will be presented at the launch seminar.

https://www.forskningsradet.no/arrangementer/2025/lansering-rapport-evalmedhelse/